Synthetic Biology: Global Markets

Report Highlights

The global synthetic-biology market reached nearly $3.9 billion in 2016 and should reach $11.4 billion by 2021, growing at a compound annual growth rate (CAGR) of 24.0% through 2021.

Report Includes

• An overview of the global markets for synthetic biology.
• Analyses of global market trends, with data from 2015, estimates for 2016, and projections of compound annual growth rates (CAGRs) through 2021.
• Coverage of core synthetic biology products: synthetic genes, other DNA parts, chassis organisms, synthetic cells
• Coverage of enabling technologies: DNA sequencing, oligonucleotides, specialty media, bioinformatics
• Coverage of enabled technologies: biofuels, specialty chemicals, diagnostics, pharmaceuticals, agriculture 
• Analysis of the synthetic biology industry structure, competitors and intellectual property landscape
• An assessment of the products and technologies most commercially viable in the immediate and near-future time frame.
• Profiles of major players in the industry

Report Scope

The study scope includes core synthetic-biology products (synthetic genes, biobrick parts, delivery plasmids, chassis organisms, synthetic cells, production systems), enabling technologies (DNA sequencing, DNA synthesis and assembly, genome editing, bioinformatics and specialty media) and enabled technologies (biofuels, chemicals, pharmaceuticals, agriculture) that are already commercialized or are forecast to be commercialized within the next five years.

We analyze key synthetic-biology technologies and products to determine present and future market status, and forecasted growth from 2016 through 2021. We also discuss strategic alliances, industry structures, competitive dynamics, patents and market driving forces.

BCC Research examines the synthetic-biology industry by market segment, including the following segments: DNA sequencing; DNA synthesis; genome editing; synthetic-biology foundries; industrial biotechnology; pharmaceuticals; and agriculture. The role of key strategic alliances and acquisitions from 2014 through 2016 is discussed. Emerging markets including synthetic genes, synthetic-biology-enabled drugs and vaccines, genome-edited crops, chassis organisms, as well as metabolically engineered factories for producing synthetic fuels and specialty chemicals are analyzed, and more than 135 companies in these fields are highlighted.

Analyst Credentials

John Bergin has produced successful and highly regarded market research reports in the life science industry for BCC research for more than 10 years. Mr. Bergin has held business development and international sales and marketing positions with Corning Inc., an advanced materials company. He has also held executive management positions with IBC Advanced Technologies, a molecular recognition company specializing in separations. Mr. Bergin's extensive expertise in commercializing new technologies is reflected in his market research reports.

Mr. Bergin received a BS degree in Chemistry and Masters of Business Administration (MBA) degree from Brigham Young University and an MS degree in biotechnology from Johns Hopkins University. John Bergin is a pseudonym of the author.